Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00357435
Other study ID # 040008
Secondary ID 04-EI-0008
Status Completed
Phase
First received
Last updated
Start date October 6, 2003
Est. completion date July 21, 2016

Study information

Verified date July 21, 2016
Source National Institutes of Health Clinical Center (CC)
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This study will explore the clinical and hereditary (genetic) features of corneal dystrophy and other inherited corneal disease. Corneal dystrophy is clouding of the cornea - the transparent part of the eye covering the iris and pupil that passes light to the back of the eye. When the cornea becomes cloudy, interfering with the passage of light, vision may be impaired or lost. Corneal problems may occur with vision problems alone, or with other problems, such as changes in facial appearance or bone or joint problems. A better understanding of these genetic conditions may help in the development of better diagnostic tests and methods of disease management.

Patients with corneal dystrophies and related corneal disease and their family members may be eligible for this study. Participants will be drawn from patients enrolled in other studies of corneal dystrophy at the NEI and collaborating clinics.

Participants will undergo the following tests and procedures:

- Medical and surgical history

- Verification of diagnosis

- Construction of a family tree regarding familial vision problems

- Complete eye examination, including dilation of the pupils and photography of the cornea, tests of color vision, field of vision, and the ability to see in the dark, and photographs of the eye.

- Blood sample collection to identify the genes responsible for corneal disease and ascertain how they cause disease.


Description:

Objective: This project, Clinical and Molecular Studies in Families With Corneal Dystrophy or Other Inherited Corneal Diseases will study the inheritance of corneal dystrophy and other inherited corneal diseases, both Mendelian and complex in order to identify the genes that, when mutated, cause corneal disease and the pathophysiology through which they act.

Study Population: Families of many nationalities and ethnic backgrounds. We will study a maximum or 2,000 patients and family members.

Design: The study consists of ascertaining individuals, and especially families with multiple individuals, affected by corneal dystrophy and other inherited corneal diseases. These patients and their families will undergo detailed ophthalmological examinations to characterize their corneal disease and determine their affectation status. A blood sample will be collected from each individual for isolation of DNA and in some individuals for lymphoblastoid transformation to establish a renewable source of DNA. Linkage analysis, physical mapping, and mutational screening will be carried out to identify the specific the gene and the mutations in it that are associated with corneal disease in this family. If necessary, the gene product will be characterized biochemically. All associate investigators will carry out patient ascertainment, diagnosis, and sample referral, and in some cases molecular genetic analyses. The study will enroll subjects at NEI and collaborating institutions.

Outcome Measures: Linkage will be determined using the lod score method and mutations in specific genes will be assessed using a combination of residue conservation, blosum score, and molecular modeling. Biochemical, metabolic, and physiological effects will be individualized to the specific assay.


Recruitment information / eligibility

Status Completed
Enrollment 86
Est. completion date July 21, 2016
Est. primary completion date
Accepts healthy volunteers No
Gender All
Age group 4 Years and older
Eligibility - INCLUSION CRITERIA:

Subjects with the following will be recruited:

1. Individuals or family members of individuals with corneal dystrophies and related corneal diseases.

2. Adults must be capable of providing their own consent.

3. All subjects must be able to cooperate with study examination and phlebotomy.

4. Older than 4 years of age.

EXCLUSION CRITERIA:

1. Diseases, infections, or trauma that mimic corneal diseases.

2. Children requiring sedation for study procedures.

Study Design


Locations

Country Name City State
China Zhongshan Opthalmic Center Guangzhou
Italy Seconda Universita degli Naples
United States National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda Maryland
United States Cleveland Clinic Cleveland Ohio
United States University of Texas, Houston Houston Texas
United States Jules Stein Eye Institute, UCLA Los Angeles California

Sponsors (1)

Lead Sponsor Collaborator
National Eye Institute (NEI)

Countries where clinical trial is conducted

United States,  China,  Italy, 

References & Publications (3)

Jiao X, Munier FL, Iwata F, Hayakawa M, Kanai A, Lee J, Schorderet DF, Chen MS, Kaiser-Kupfer M, Hejtmancik JF. Genetic linkage of Bietti crystallin corneoretinal dystrophy to chromosome 4q35. Am J Hum Genet. 2000 Nov;67(5):1309-13. Epub 2000 Sep 21. — View Citation

Klintworth GK, Sommer JR, Obrian G, Han L, Ahmed MN, Qumsiyeh MB, Lin PY, Basti S, Reddy MK, Kanai A, Hotta Y, Sugar J, Kumaramanickavel G, Munier F, Schorderet DF, El Matri L, Iwata F, Kaiser-Kupfer M, Nagata M, Nakayasu K, Hejtmancik JF, Teng CT. Familial subepithelial corneal amyloidosis (gelatinous drop-like corneal dystrophy): exclusion of linkage to lactoferrin gene. Mol Vis. 1998 Dec 31;4:31. — View Citation

Lee J, Jiao X, Hejtmancik JF, Kaiser-Kupfer M, Chader GJ. Identification, isolation, and characterization of a 32-kDa fatty acid-binding protein missing from lymphocytes in humans with Bietti crystalline dystrophy (BCD). Mol Genet Metab. 1998 Oct;65(2):143-54. — View Citation

See also
  Status Clinical Trial Phase
Completed NCT05114928 - Correlation Between Q-value Changes and Progression of Pediatric Keratoconus.
Recruiting NCT06160960 - Influence of Pupillary Behavior During Eye Surgery on Morphological and Functional Outcome
Completed NCT04484402 - Treatment of Patients With Inflammatory-dystrophic Diseases of the Cornea Using Autologous Stem Cells Phase 1/Phase 2
Not yet recruiting NCT05581875 - A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Pomalidomide and Dexamethasone in Patients With Relapsed/ Refractory Multiple Myeloma Previously Treated With One Line Therapy Who Are Lenalidomide Refractory Phase 1/Phase 2
Recruiting NCT06101017 - Developing a Nationwide Registry to Track Longitudinal Clinical Outcomes of Corneal Surgery and Disease
Withdrawn NCT03421548 - Implantable Intraocular Pressure Sensor for Glaucoma Monitoring in Patients With Boston Keratoprosthesis Type 1 N/A
Withdrawn NCT05700864 - NGF Treatment for Patients With Neuropathic Corneal Pain Phase 1
Enrolling by invitation NCT05758753 - QST for Corneal Nerve Function N/A
Terminated NCT00001310 - Tissue Studies of Human Eye Diseases
Completed NCT02386774 - Innovative Imaging of the Conjunctiva, Cornea, and Ocular Adnexa N/A
Recruiting NCT05694247 - Study to Evaluate the Clinical Safety and Performance of the CorNeat KPro for Treatment of Corneal Blindness N/A
Not yet recruiting NCT06294015 - Efficacy of 20% Autologous Serum Drops in the Treatment of Corneal Epitheliopathy Associated With Antihypertensive Glaucoma Drops. Phase 4
Completed NCT00654888 - Automated Lamellar Keratectomy in Symptomatic Patients With Bullous Keratopathy N/A
Recruiting NCT04251143 - Dresden Corneal Disease and Treatment Study
Withdrawn NCT02374723 - Evaluation of Biosynthetic Constructs to Replace Donor Corneas Phase 1
Completed NCT01384487 - Nidek RS3000 Comparative Study N/A
Completed NCT00804505 - Hybrid SA RGP Center/S-H Skirt Daily Wear 90 Day Multicenter Study N/A
Completed NCT04475900 - Computer-aided Diagnosis of Ocular Diseases Based on Corneal Biomechanics
Recruiting NCT05573802 - A Study to Investigate Safety and Clinical Activity of Belantamab Mafodotin in Combination With Lenalidomide, Dexamethasone and Nirogacestat in Patients With Transplant Ineligible Newly Diagnosed Multiple Myeloma Phase 1/Phase 2
Terminated NCT04485858 - First in Human (FIH) Study to Assess Safety and Efficacy of the CorNeat KPro for the Treatment of Corneal Blindness N/A